Malaysia on track to become healthcare hub
However, the research house said it believes challenges persist due to the country's ageing population, increasing prevalence of non-communicable diseases and communicable diseases, as well as financing pressures.
'The challenges are no longer just about basic access, which has largely been achieved in Peninsular Malaysia, but about quality, efficiency, equity and sustainability in the face of rising costs and demand.
'Malaysia is not adhering rigidly to one ideological model – fully public or fully private. Instead, it's embracing a pragmatic, dual-tier system with increasing public-private partnerships,' the research house said.
It pointed out that the Malaysian healthcare industry is in a critical phase of transformation, where the success of the journey will depend on the ability to effectively implement strategic changes.
MBSB Research added that the country has a strong foundation in the healthcare sector as well as a clear understanding of its complex challenges and an ambitious roadmap for reform.
The research house believes the country will need to sustain the political will to navigate the inherent difficulties of comprehensive reforms, ultimately aiming for a truly equitable, high-quality and sustainable healthcare system for all.
It said it believes that the government's continued heavy subsidisation of public healthcare and the active pursuit of universal health coverage through various initiatives demonstrate a fundamental commitment to ensuring that healthcare remains a right for all citizens.
This was evident by the Budget 2025's allocation of RM45.3bil for the local healthcare sector. 'The willingness to address high out-of-pocket payments also directly signifies a focus on financial-risk protection for its citizens,' it said.
It added that the Health Ministry's emphasis on digitalisation, data analytics and value-based healthcare also indicates a forward-looking approach.
MBSB Research maintained its 'positive' stance on the sector due to its resilient support from the government, the drive from ongoing trends and the leverage of contributing to local and regional economies.
It expects the Malaysian healthcare sector's overall revenue to grow at a five-year compound annual growth rate of between 6% and 8% up to 2030.
Its top pick for the sector is KPJ Healthcare Bhd , as it is well-positioned to capitalise on the sector's positive outlook due to its established market presence, strategic growth initiatives and improving financial performance.
'With its large network of private hospitals (30 hospitals and four ambulatory care centres), the group has strong brand recognition across the country while serving the growing domestic demand for quality and affordable private healthcare services,' the research house said.
KPJ also has the advantage of improving its operational efficiencies through its 'KPJ Health System' framework, while heavily investing in digital capabilities with about RM400mil allocated for digitalisation and advanced medical technology.
'Overall, KPJ's robust growth strategy, strong financial performance and leading market position in a structurally growing sector make it an attractive proposition in the Malaysian healthcare landscape,' MBSB Research added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Health Ministry, MCMC to use drones and telehealth to boost rural healthcare access
Health Ministry and MCMC officials at the launch of the drone medicine delivery pilot project. KOTA KINABALU: A strategic collaboration between the Health Ministry (MOH) and the Malaysian Communications and Multimedia Commission (MCMC) will see digital healthcare services extended to rural and interior areas of Sabah, including the delivery of medicine using drones. In a joint statement on Wednesday (July 23), MOH and MCMC said the pilot drone project will be based at the Tawau Health Clinic and will serve two nearby National Information Dissemination Centres (Nadi). Sabah was selected for the pilot due to its high 4G and 5G coverage — 94.4% and 69% respectively — as well as its geographical challenges that demand innovative solutions to ensure continued treatment and medicine access. The collaboration will encompass eight major initiatives: upgrading communications infrastructure to support future healthcare needs; equipping rural clinics, including rural and community clinics, with computers and electronic medical record (EMR) systems; installing telehealth kiosks at Nadi centres; delivering medicine using drones to remote areas; implementing cybersecurity measures at health facilities; providing adaptation grants for EMR systems; establishing a Smart Hospital Innovation Hub; and strengthening Malaysia's participation in global digital health platforms. A drone takes off during the demonstration at a NADI centre. The initiative will also enable cloud-based systems and virtual consultation platforms to support treatment continuity, follow-up care, and medicine delivery to hard-to-reach areas. A key focus is also placed on enhancing digital health literacy among rural communities to boost public confidence in the safety and effectiveness of these services. 'MOH welcomes this partnership as it strengthens the public healthcare system through innovative, people-friendly solutions. It is a crucial approach to tackle today's healthcare challenges, especially in hard-to-access areas,' said Health Minister Datuk Seri Dr Dzulkefly Ahmad in the statement. With 1,099 Nadi centres nationwide acting as digital gateways, the public — including those in rural areas — will be able to access virtual consultations and telehealth services, furthering the national goal of '1 Individual, 1 Record' and reinforcing the digital health ecosystem. The ministry said this move also supports Malaysia's aspiration to become a regional leader in digital health and a global hub for health innovation in line with the Madani government's vision.
Barnama
3 hours ago
- Barnama
Malaysian Doctors Help More Cambodian Kids Smile with Pride in Latest Mission
By Vijian Paramasivam PHNOM PENH, July 23 (Bernama) -- Smile Cambodia, led by a team of Malaysian doctors, is transforming the lives of children with facial deformities and offering renewed hope to underserved communities without access to professional care. The independent charity organisation that largely depends on volunteer doctors, both foreign and local, successfully conducted complicated surgeries on children suffering from cleft lip and cleft palate anomalies last weekend. bootstrap slideshow The recent mission was held at the Smile Centre in Khmer-Soviet Friendship Hospital in Phnom Penh, where three Malaysian specialists participated in the reconstructive surgeries, along with Cambodian experts. Sixty patients were screened at the centre from July 17 to 19. 'The recent surgical mission is our fourth this year. We had targeted to treat 30 patients during the two-day surgical mission. We treated 44 patients, including many difficult cases. 'Many parents of cleft patients expressed their happiness and gratitude when they left the hospital. Our surgical mission was a success,' Smile Cambodia Vice Chairman and Executive Director Chan Kok Choy told Bernama. The organisation, led by Chan, a former Malaysian banker turned social worker based in Cambodia, brings joy to children suffering from facial deformities, alleviates pain for their parents and introduces advanced medical surgeries to rural communities. 'We are grateful to both our Malaysian and Cambodian medical volunteers for their professionalism, commitment, hard work and dedication to treat every patient with care.
Focus Malaysia
8 hours ago
- Focus Malaysia
Southeast Asia pharma market set to outgrow global average
SOUTHASIA Asia (SEA) presents a substantial future prospect for the pharmaceutical market. Its projected growth rate significantly outpaces the global average and other major established markets. As of calendar year 2024 (CY24), global total market size for pharmaceuticals is estimated at USD1.5 tri. In comparison, SEA's total market size is estimated at USD27 bil. The significant growth for SEA indicates that ASEAN is a prime growth engine for the global pharmaceutical industry. This makes it an attractive destination for investment and market expansion. The Philippines and Malaysia show steady growth in a biosimilar export potential, reaching USD 111 mil and USD 70 mil respectively by 2027. Malaysia's growth, though robust, is relatively smaller in absolute terms compared to Thailand, Vietnam, and Indonesia. However, companies like Duopharma and Pharmaniaga are actively developing Halal-certified biosimilars. Overall, biosimilars is an untapped potential due to increasing healthcare demands and cost pressure. 'We believe that investing in local manufacturing of biosimilars can open avenues for SEA countries to export,' said MBSB Research. Countries that prioritise and invest in local biosimilar production are likely to become stronger exporters in this field. This aligns with the broader trends of high pharmaceutical market growth in SEA driven by demographics, NCDs, and the increasing sophistication of healthcare systems, all of which necessitate tailored and creative market strategies. Malaysia's pharmaceutical sector boasts a strong and strategically recognized local manufacturing base that significantly contributes to medicine security, especially for generics and essential medicines. While Malaysia demonstrates capabilities in exporting to highly regulated markets like the USA, it remains heavily reliant on imports for patented drugs, biologics, vaccines, and key APIs. The main challenge for Malaysia lies in bridging this gap by further boosting local R&D, attracting more sophisticated manufacturing capabilities, and strengthening its position in the global pharmaceutical value chain beyond just generics. 79% of total volume of generic medicines and 47% of items listed in National Essential Medicines List (NEML) are locally produced. However, most drugs, notably patented medicaments, immunoglobulins, human vaccines and insulins, are still dependent on imports. Malaysia consistently shows widening trade deficit underscores Malaysia's high reliance on imported pharmaceuticals. While local production is strong in generics, the country still depends heavily on foreign sources for innovative, patented, and specialised medicines. This reinforces the government's strategic focus on local manufacturing and technology transfer to enhance medicine security and reduce import dependency in the long run. The overall trend in the regional and local pharmaceutical market suggests that both domestic and foreign investors will see growing opportunities in Malaysia. The 51% FDI / 49% DDI ratio suggests a healthy balance between local commitment, and global capital and expertise. FDI indicates that Malaysia is highly attractive to foreign pharmaceutical companies, bringing in capital, technology, and global best practices, while DDI signifies robust local entrepreneurship and investment from Malaysian companies, demonstrating confidence in the domestic market and capabilities. We opine that the untapped drug manufacturing ecosystem will continue to follow the megatrend of new innovative drugs – including biologics, biosimilars and cell & gene therapy drugs – and open more opportunities for Malaysia to be a major healthcare hub in the region. While direct pharmaceutical exports from Malaysia to the US might face immediate headwinds from tariffs, the broader impact on Malaysia's healthcare subsector could come from indirect effects on global pharmaceutical supply chains and procurement costs. This would affect the affordability and availability of medicines within Malaysia for all citizens and healthcare providers. The Malaysian government and industry players are already responding by prioritizing supply chain diversification and exploring domestic production enhancements to mitigate these risks. Meanwhile, we believe a multi-pronged approach involving government action, industry adaptation, and consumer awareness will be crucial. Overall, we maintain positive on the healthcare sector. The pharmaceutical market is fundamentally driven by robust demographic trends, which naturally increases the demand for healthcare services and medicines. —July 23, 2025 Main image: Daily Sabah
